The updated data showed positive results and supports the company’s aim to start a Phase 111 trial later this year.

Takeda Pharmaceutical Company Limited (NYSE:TAK)’s ADCETRIS® (brentuximab vedotin) in combination with ECADD was authorized ...

Truist Securities analysts raised the price target on BioNTech SE (NASDAQ:BNTX) from $151 to $155 and kept a “Buy” rating.

From the Cox Laboratory for Biomedical Engineering, Rice University, Houston, Tex (N.A.T, J.L.M., L.V.M.); the Department of Medicine, Baylor College of Medicine ...

This article reports the design, synthesis, and evaluation of a novel class of molecules of intermediate size (approximately 7000 Da), which possess both the targeting and effector functions of ...